CELLVIE
DEAD

Serial Number

79286017

Owner

Cellvie UG (haftungsbeschränkt)

Attorney

Bruce Londa

Filing Date

Dec 18, 2019

Add to watchlist:

No watchlists yet
View on USPTO

CELLVIE Trademark

Serial Number: 79286017

CELLVIE is a trademark filed by Cellvie UG (haftungsbeschränkt) on December 18, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Cellvie UG (haftungsbeschränkt) (2 trademarks)

Speditionsstraße 15A

Entity Type: 16

cellvie Inc. (2 trademarks)

4326B Scotland Street

Entity Type: 98

Trademark Details

Filing Date

December 18, 2019

Registration Date

Not Registered

Goods & Services

Preparations for medical purposes employing mitochondria; cardiovascular treatment preparations employing mitochondria; cardiovascular pharmaceuticals employing mitochondria used in treating arrhythmias; pharmaceutical and biological preparations for the treatment of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies, tumors or diabetes mitochondria for transplant purposes for medical use; pharmaceutical and biological preparations for the application of mitochondria transplantation for medical purposes in vessel and organ transplantations; implantable living tissue and mitochondria for the promotion of tissue growth, for medical use; mitochondria, for medical use; biological tissue cultures containing mitochondria for medical purposes; pharmaceutical and biological preparations containing mitochondria for tissue regeneration and protection for medical purposes; living cell components, namely, mitochondria, including genetically-modified mitochondria or pharmaceutically treated mitochondria, for medical use in humans and veterinary use in animals

Medical testing services for diagnostic and disease treatment purposes relating to cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of human or animal tissues for mitochondria transplant treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors; medical analysis of cells and cell components in relation to mitochondria for diagnostic and treatment purposes of cardiovascular diseases, ischemia-and reperfusion-injuries, chronic cardiac diseases, mitochondrial myopathies and tumors

Prosthetic tissues based on mitochondria for parietal, vascular and visceral use; medical apparatus and devices for the processing of tissue- or cell-samples for the isolation of mitochondria or other cell components, namely, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from muscle tissue or other human or animal tissues, as well as from cells and cell cultures; filter for the isolation of cell components, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles from cells for medical purposes; medical apparatus and devices for the transplantation or injection of cells or cell component, namely, mitochondria, nucleus, ribosomes, rough endoplasmic reticulum, smooth endoplasmic reticulum, golgi apparatus, vacuole, chloroplasts, peroxisome, lysosome, centrosome, centriole, cilium, microvillus, cytosol, cytoskeleton, microtubules, filaments, exosomes, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), micro RNA (mRNA), transfer RNA (tRNA), nucleic acid, cell membrane, plasma membrane and secretory vesicles in humans or animals

Scientific and technological services, namely, scientific and clinical research, analysis and testing in the field of mitochondrial isolation or transplantation; scientific and clinical research and development services in the field of mitochondria; conducting clinical trials for others in the field of cardiovascular diseases, ischemia-and reperfusion-injuries, heart transplantations, tumor treatments, mitochondrial myopathies analysis of human tissues for scientific and clinical research relating to mitochondria; scientific and clinical research, analysis and testing services relating to the isolation and cultivation of human and animal mitochondria

Filing History

CHANGE OF OWNER RECEIVED FROM IB
Sep 20, 2024 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 7, 2022 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Oct 17, 2022 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 15, 2022 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 9, 2022 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 22, 2021 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 22, 2021 OPNR
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Oct 15, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 15, 2021 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Mar 29, 2021 GNFN
FINAL REFUSAL E-MAILED
Mar 29, 2021 GNFR
FINAL REFUSAL WRITTEN
Mar 29, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 5, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 5, 2021 CRFA
ASSIGNED TO LIE
Mar 5, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 3, 2020 TROA
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
Oct 16, 2020 CORR
REFUSAL PROCESSED BY IB
Jul 31, 2020 RFNT
CORRECTION TRANSACTION RECEIVED FROM IB
Jul 17, 2020 CRCV
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 29, 2020 RFCS
REFUSAL PROCESSED BY MPU
Jun 29, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 29, 2020 RFCR
NON-FINAL ACTION WRITTEN
May 28, 2020 CNRT
APPLICATION FILING RECEIPT MAILED
May 26, 2020 MAFR
ASSIGNED TO EXAMINER
May 22, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 22, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 21, 2020 REPR